Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.
about
Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individualsFirst-line beta-blockers versus other antihypertensive medications for chronic type B aortic dissectionFirst-line beta-blockers versus other anti-hypertensive medications for chronic type B aortic dissectionsPharmacotherapy for hypertension in the elderlyCanadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trialsAngiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patientsA novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trialsMechanical stretch potentiates angiotensin II-induced proliferation in spontaneously hypertensive rat vascular smooth muscle cellsComparing angiotensin II receptor blockers on benefits beyond blood pressureFrom hypertension to stroke: mechanisms and potential prevention strategies.A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitorsComparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis.Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update.Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials.A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention.Cardio classics revisited--focus on the role of candesartan.Clinical Interaction between Brain and Kidney in Small Vessel DiseaseSafety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational studyThe therapeutic role of RAS blockade in chronic heart failure.Usefulness of a large automated health records database in pharmacoepidemiology.Primary stroke prevention and hypertension treatment: which is the first-line strategy?Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular riskLower heart rate in the early postoperative period does not correlate with long-term outcomes after repair of type A acute aortic dissectionThe impact of dose of the angiotensin-receptor blocker valsartan on the post-myocardial infarction ventricular remodeling: study protocol for a randomized controlled trial.Clinical neuroprotective drugs for treatment and prevention of stroke.Evaluation of dosing time-related anti-hypertensive efficacy of valsartan in patients with type 2 diabetes.The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan.Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review.Chronic heart failure in Japan: implications of the CHART studies.The healthcare burden of hypertension in Asia.Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.Acute aortic syndromes and thoracic aortic aneurysm.Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension.Protective effects of renin-angiotensin blockade beyond blood pressure control.Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine.Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design.Significance of genetic polymorphisms of the renin-angiotensin-aldosterone system in cardiovascular and renal disease.Blood pressure responder rates versus goal rates: which metric matters?The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man
P2860
Q24186039-02496A78-2C16-4A80-99CA-D0D32D26399EQ24200255-7D77F504-FDA4-4986-A671-7CFA9B238DE1Q24200438-11812A54-BB90-45B0-AA76-1CA1870484B5Q24240189-4049A5A2-598D-4CC5-A96F-F90FB5DD468DQ24650348-C6347832-AF38-41F6-AA02-5FC6D4F6A63FQ27023161-460F13F0-B70B-4FC7-9419-D3D5CD5CF35BQ28472432-2060413D-6CFB-4742-A053-0BF19A0D3DEFQ28571873-7315A95D-B293-43A8-B4A3-CA7FFC582396Q30360678-88A238B3-C600-4591-9C2F-5BE9AE6E3FBFQ30407495-F0C6B333-261A-458D-9615-AF11B2C202DDQ30432209-B1EACA9D-542E-4A2F-B2C6-15AC15035BD9Q30514101-84335768-4388-4873-954B-5666D5F4A19EQ33403831-1D2E6510-4763-4420-8C02-DDBB10FCA96FQ33797646-2AF1A5C7-C2E5-4718-92FA-3B5AC9CA2B5FQ33803829-B765A3A5-A8CE-4B25-98C1-524532ED3B42Q34018990-878FCE33-9782-4AD8-BDE5-358F9C1C571FQ34417462-3AAEE679-94CD-4F21-9F74-7084390E79ADQ34512756-9AD44B6A-BC69-4DEF-BB47-1ACEAF534726Q34647575-D7180142-8520-49C8-9DBA-6339C1B4ABB7Q34915602-AA8E7665-48DD-4D7F-9DC3-B3EE8998D89CQ35166816-9B78E096-E47D-43BD-B54C-41489F0AF2BEQ35513559-EEC72D77-309B-479B-96D2-3DD378857D75Q35539305-0A96FEA9-3662-4F72-86E7-33EC8499ECD1Q35594070-DDEC5DA0-37B9-43D1-B40D-97886B449C10Q35639351-AE557452-7C83-4394-BD00-E3DDE98DBE38Q36097037-4A10CDDF-F2A5-4666-A298-F1481C833112Q36357375-58B299F6-C22F-46BB-917C-7936FB9533B2Q36359042-F3813772-BA93-43BD-B043-ACE0ABC5AB51Q36705836-DC75A69B-9180-4570-836D-8DA17306A77DQ36766968-A673E8F8-CEDC-4911-A4C2-FCB3AB41FE2DQ36801003-F4857C07-4B44-4C9B-8B9B-B8B08837481EQ36929276-C1B643A9-AE54-482C-B7C7-8F1261C35187Q37176692-CC4D522D-7A7B-4F03-89C2-B4CAB1B10A18Q37199928-C49516C1-B174-4458-875A-257A3E61EC19Q37384710-9669ADF1-07FF-46D2-91A0-0F3F4E83C946Q37390740-453553E5-1FA0-4138-AFC6-DB45FEC916E3Q37406871-5192C6C1-9E9D-49C8-B1C0-D7E6BF13A729Q37416129-69AAD2D1-F0D1-4D4E-A1F0-B44D6FE8C915Q37418547-3A0C49E8-1E71-4E92-B4CB-F793F8C1F408Q37479070-02727E27-829E-4400-9F4E-7E14E4727291
P2860
Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Valsartan in a Japanese popula ...... int morbidity-mortality study.
@en
type
label
Valsartan in a Japanese popula ...... int morbidity-mortality study.
@en
prefLabel
Valsartan in a Japanese popula ...... int morbidity-mortality study.
@en
P2093
P1433
P1476
Valsartan in a Japanese popula ...... int morbidity-mortality study.
@en
P2093
Fumiko Okazaki
Ikuo Taniguchi
Jikei Heart Study group
Katsunori Ikewaki
Kazuhiko Ogawa
Kiyoshi Kanae
Makoto Kawai
Makoto Ohta
Makoto Yoshikawa
Masayuki Taniguchi
P304
P356
10.1016/S0140-6736(07)60669-2
P407
P50
P577
2007-04-01T00:00:00Z